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Summary
Objective: To investigate the effect of long-term exposure to glucosamine or mannosamine on the catabolism of aggrecan by explant cultures
of bovine articular cartilage maintained in the presence of retinoic acid.
Design: The kinetics of loss of 35S-labeled and total aggrecan from explant cultures of bovine articular cartilage maintained in the presence
of 1 µM retinoic acid and exposed to varying concentrations of glucosamine or mannosamine was investigated over a 9-day culture period.
In other experiments, the reversibility of the inhibition of aggrecan catabolism by glucosamine or mannosamine was investigated in cultures
exposed to these amino sugars for the first 5 days of a 15-day culture period. The metabolism of chondrocytes exposed to these amino
sugars was evaluated by measurement of lactate production or 3H-serine and 35S-sulfate incorporation into protein and glycosaminoglycans,
respectively. The direct effect of these amino sugars on soluble aggrecanase activity was determined from immunoblots of aggrecan digests.
Results: Glucosamine at 5 mM concentration and mannosamine at 2 mM concentration inhibited degradation of radiolabeled and chemical
levels of aggrecan. At concentrations of up to 10 mM amino sugars, the metabolism of chondrocytes was not impaired, as determined by
lactate production, protein synthesis and the incorporation of 35S-sulfate into proteoglycans. These amino sugars did not inhibit soluble
aggrecanase activity. The exposure of articular cartilage explants to 5 mM glucosamine or mannosamine for 5 days in culture in the presence
or absence of retinoic acid did not provide long-term suppression of stimulated aggrecan loss.
Conclusions: This study indicates that continuous presence of amino sugars is required to protect cartilage from stimulated loss of aggrecan.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
The loss of aggrecan from the extracellular matrix of
articular cartilage results in a change in biomechanical
properties of the tissue, which precede the loss of cartilage
from the surface of bones. The degradation of aggrecan in
normal and degenerative cartilage and in explant cultures
stimulated with retinoic acid or cytokines IL-1, TNF-α has
been shown to be primarily due to the action of
aggrecanases1–3. In addition, there is a strong correlation
between the increase in aggrecanase-derived metabolites
and the levels of chemical and radiolabeled glycos-
aminoglycans present in the medium of retinoic acid-
stimulated cultures2–6. The metabolites that can be
attributed to other proteinases, such as MMPs, have only
been detected, at a late stage of tissue degradation, as
minor products3. Aggrecanase activity has been attributed
to three enzymes, ADAMTS-1, ADAMTS-4 and ADAMTS-5
(a disintegrin and metalloproteinase with thrombospondin
(TBS) motifs), that cleave aggrecan at specific sites be-
tween a glutamate and a hydrophobic residue that are
located within the interglobular domain and the chondroitin
sulfate attachment regions of the core protein of this
proteoglycan. Aggrecanases are secreted metalloprotein-
ases with furin and cysteine switch activation sites and
other domains that include one or more TBS type 1 motifs,
spacer region, disintegrin and cysteine-rich domains capa-
ble of interacting with extracellular matrix components7–10.
Such interactions have been proposed to be important in
the regulation of activity of these enzymes. The mature
enzymes have been reported to be inactive, and the activity
is generated by carboxy-terminal truncation of aggreca-
nase proteins11,12. The aggrecan-degrading activity of trun-
cated aggrecanase proteins has also been reported to
depend on the retention of some carboxy-terminal regions,
such as a disintegrin and TBS 1 motif in ADAMTS-410,12.
The carboxy-terminal regions in aggrecanases may also
have a role in the inhibition of the enzyme activity by highly
sulfated polysaccharides, such as heparin, heparan sulfate
and calcium pentosan polysulfate13. A number of studies
have shown that the amino sugars, glucosamine and
mannosamine, inhibited IL-1, TNF-α and retinoic acid-
stimulated aggrecanase degradation of aggrecan in
cartilage and chondrocyte cultures4,5,14. In addition, glu-
cosamine has been used as a nutritional supplement for
treatment of osteoarthritis with positive results relating to
narrowing of joint space and symptomatic relief15. The
effect of glucosamine as an antiarthritic agent is
poorly understood, especially the cellular and molecular
mechanisms of its action.
The present study investigates the long-term effect of
glucosamine and mannosamine on retinoic acid-stimulated
degradation of aggrecan in bovine articular cartilage cul-
tures, as well as their impact on the metabolism of articular
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cartilage. Also investigated in this study is the potential of
these amino sugars to directly affect aggrecanase activity
and the ability to protect cartilage from aggrecanase-
induced loss of aggrecan.
Materials and methods
Dulbecco’s modified Eagles medium (DMEM) containing
1 g/l (5.5 mM) glucose, newborn calf serum (NBCS), non-
essential amino acids, penicillin and streptomycin were
purchased from CSL (Melbourne, Australia). Mannosamine
and chondroitinase ABC were from ICN Biomedicals Inc.
(Costa Mesa, CA, USA). Carrier-free [35S]sulfate in
aqueous solution and [3H]-L-serine were from DuPont
New England Nuclear (Boston, MA, USA). Retinoic acid,
glucosamine, keratanase and a lactate assay kit were
from Sigma Chemical Co. (St. Louis, MO, USA). Biotin-
conjugated antibody to mouse immunoglobulin (raised
in sheep) and peroxidase-conjugated streptavidin were
purchased from Silenus Laboratories (Hawthorn, Victoria,
Australia). The monoclonal antibody 5/6/3-B-3 was kindly
provided by Professor B. Caterson (School of Molecular
and Medical Biosciences, University of Wales at Cardiff,
UK). Immobilon-P (polyvinylidene difluoride) membranes
were from Millipore (Belford, MA, USA) and PD-10 columns
were from Amersham Pharmacia Biotechnology (Uppsala,
Sweden).
EXPLANT CULTURES OF BOVINE ARTICULAR CARTILAGE
Articular cartilage, freshly dissected from meta-
carpophalangeal joints of 1–3 years old cattle was incu-
bated in DMEM containing 20% (v/v) NBCS and 30 µCi/ml
of [35S]sulfate for 6 h at 37°C. The cultures were main-
tained in the absence of NBCS for the reminder of the
culture period in all proteoglycan turnover experiments. In
this work, 5.5 mM glucose was present in the culture
medium, which reflects the physiological concentration of
glucose reported for cartilage16. The tissue was washed
with DMEM to remove unincorporated [35S]sulfate. Dupli-
cate cultures containing 100 mg wet-weight tissue/4 ml
medium were maintained in either DMEM alone or DMEM
containing 1 µM retinoic acid and 0, 2, 5 or 10 mM
glucosamine or 0, 1.5, 5 or 10 mM mannosamine for a
further 9 days. The medium was changed daily, and the
spent medium was collected and stored in the presence of
proteinase inhibitors at −22°C17. On completion of the
experiment, the tissue was extracted with 4.4 ml of 0.5 M
NaOH for 24 h at room temperature. In a separate exper-
iment, freshly dissected articular cartilage was incubated
with radiolabeled sulfate as described previously, and du-
plicate cultures of 100 mg wet-weight tissue/4 ml medium
were maintained for 5 days in DMEM containing either
5 mM glucosamine or mannosamine in the absence or
presence of 1 µM retinoic acid and then returned to culture
for another 10 days in DMEM containing retinoic acid. The
control cultures were maintained for 15 days in either
DMEM or DMEM containing 1 µM retinoic acid or for 5 days
in DMEM and then continued for another 10 days in DMEM
containing 1 µM retinoic acid.
MEASUREMENT OF TURNOVER OF 35S-LABELED AGGRECAN
To determine the amount of radiolabeled macro-
molecules in medium samples and in tissue extracts, the
samples were applied to Sephadex G-25 columns (PD-10
columns) equilibrated in a dissociative buffer containing
4 M guanidine hydrochloride. The excluded volume peak
was analyzed for radioactivity. The percentage of 35S-
labeled aggrecan remaining in the matrix on each day of
culture was determined from the amount of 35S-labeled
macromolecules appearing in the medium on each day of
culture and that remaining in the matrix at the end of the
culture period, as previously described18.
MEASUREMENT OF GLYCOSAMINOGLYCAN LEVELS
The levels of glycosaminoglycans appearing in the
medium of explant cultures on each day and present in
tissue extracts at the end of culture period were determined
using the dimethylmethylene blue (DMB) assay for sulfated
glycosaminoglycans, using chondroitin sulfate from bovine
nasal septum as standard19. The DMB solution was added
to diluted samples and standards and appropriate blank
solutions prior to absorbance reading at 525 nm.
MEASUREMENT OF LACTATE LEVELS
The levels of lactate released into the medium of explant
cultures on days 5 and 9 were determined by the oxidase/
peroxidase method using a commercial kit from Sigma20.
MEASUREMENT OF PROTEIN AND PROTEOGLYCAN SYNTHESES
The following experiments were performed using tissue
from the same animal. Articular cartilage dissected from a
single metacarpophalangeal joint was maintained in culture
in 100 mg wet-weight tissue/4 ml medium lots in DMEM in
presence or absence of 1 µM retinoic acid and 0, 2, 5 and
10 mM glucosamine or 0, 1.5, 5 and 10 mM mannosamine
for 9 days. On days 5 and 10 of culture, the triplicate
cultures from each treatment condition were preincubated
with 2 ml DMEM at 37°C for 1 h. The medium was then
replaced with 2 ml DMEM containing 20 µCi [35S]sulfate/ml
or 30 µCi [3H]serine/ml, respectively, that were prepared as
batch solutions. Following a 2 h incubation period, the
35S-radiolabeled tissue was extracted with 0.5 M NaOH for
24 h at room temperature and the [3H]serine-radiolabeled
tissue was extracted by 4 M guanidinium chloride, 0.05 M
sodium acetate, pH 6 for 24 h at 4°C, followed by 0.5 M
NaOH for 24 h at room temperature. Radiolabeled macro-
molecules present in tissue extracts were separated from
unincorporated radiolabel by gel filtration on Sephadex
G-10 (PD-10) columns6. The rate of incorporation of 35S-
sulfate into proteoglycans and the rate of incorporation of
3H-serine into protein were expressed as cpm/100 mg
wet-weight tissue.
WESTERN BLOT ANALYSIS
Aggrecan monomer (12 µg), purified from bovine articu-
lar cartilage21, was incubated with conditioned medium
(100 µl) obtained from explant culture of joint capsule, in
the presence of 0, 2, 5, or 10 mM glucosamine or man-
nosamine for 24 h at 37°C. We have previously shown that
conditioned medium from explant cultures of bovine joint
capsule contains aggrecanase activity, and when incubated
with aggrecan, results in cleavage of core protein of this
proteoglycan at aggrecanase specific sites21. The digests
were stopped by the addition of proteinase inhibitors17.
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Aggrecan fragments were deglycosylated using chondroiti-
nase ABC (0.0125 U/mg aggrecan) and keratanase
(0.025 U/mg aggrecan) in 1 ml of 0.1 M Tris/0.1 M sodium
acetate buffer, pH 7. Samples of deglycosylated aggrecan
core protein fragments were subjected to electrophoresis
under reducing conditions on a 4–10% gradient polyacryl-
amide sodium dodecyl sulfate slab gel6. The protein bands
were electroeluted onto Immobilon-P membranes and
probed with antibody 5/6/3-B-322 to terminal unsaturated
chondroitin 6-disulfated disaccharides as previously de-
scribed6. These epitopes are present on glycosamino-
glycans stubs that remain attached to aggrecan core
protein following deglycosylation by chondroitinase ABC.
The membrane was then exposed to biotin-conjugated
second antibody followed by exposure to horseradish
peroxidase-conjugated streptavidin. The protein bands
were visualized with 2.8 mM 4-chloro-1-naphthol in a
phosphate-buffered saline containing 0.02% (v/v) hydrogen
peroxide.
TREATMENT OF DATA
In previous work using articular cartilage in explant
cultures, we have reported the variation in the absolute
rates of synthesis and catabolism of proteoglycans in
articular cartilage from different animals13. This variation
also extends to other metabolic measurements that include
lactate production, protein and proteoglycan syntheses and
the amounts of macromolecules present in the extracellular
matrix of the tissue. Thus, to circumvent the animal vari-
ation, any one experiment is restricted to tissue obtained
from a single joint. Consequently, a limited amount of tissue
is available in any one experiment and, thus, the number of
samples used for the statistical analysis of the data is
restricted. In some work presented in this article, duplicate
samples containing sufficient amount of tissue necessary to
generate accurate and reproducible data, were analyzed,
and the mean of the data is given along with the range of
values obtained. All experiments were repeated at least
three times, and all of these showed the same outcome.
In experiments measuring protein and proteoglycan syn-
theses, triplicate samples were used to compare the effect
of different treatments using the Kruskal–Wallis test (analy-
sis of variance by ranks). Significant differences between
the treatment groups were analyzed by the two-tailed
Mann–Whitney U-test, and P values of less than 0.05 were
taken as significant.
Results
EFFECT OF GLUCOSAMINE AND MANNOSAMINE ON RETINOIC
ACID-INDUCED CARTILAGE DEGRADATION
Experiments were performed to establish the effect of
varying concentrations of amino sugars on the degradation
of aggrecan in long-term cultures of articular cartilage.
Bovine articular cartilage was maintained in the presence
of retinoic acid and 0–10 mM amino sugars for 9 days in
culture, as described in Materials and Methods section.
Figure 1(A) shows the percentage of 35S-labeled aggrecan
lost from the matrix of cultures with time, for cultures
treated with glucosamine. The retinoic acid-stimulated loss
of radiolabeled aggrecan from the matrix of tissue was
inhibited in a concentration-dependent manner up to
10 mM glucosamine. At the end of culture period (day 9),
the retinoic acid-stimulated loss of radiolabled aggrecan
was reduced by 7, 13 and 58% in the presence of 2, 5 and
10 mM glucosamine, respectively. The stimulated loss of
aggrecan represents the loss above that observed for
cultures maintained in DMEM alone. Figure 1(B) shows the
loss of chemical levels of aggrecan from the matrix of
cultures in the same experiment. The stimulated loss of
chemical levels of aggrecan was also inhibited in a
concentration-dependent way by glucosamine [Fig. 1(B)].
Table I shows the chemical levels of aggrecan remaining in
the tissue at the end of culture period. There is an increase
in chemical levels of aggrecan in retinoic acid-stimulated
cultures with increasing concentrations of glucosamine. In
tissue treated with 10 mM glucosamine, there was a 53%
inhibition of aggrecan loss. It should be noted that both the
degradation and the synthesis of aggrecan contribute to
the chemical levels of aggrecan present in the tissue during
the culture period, while the levels of the radiolabeled
aggrecan reflect the loss of aggrecan from a defined pool of
aggrecan synthesized at the beginning of culture period.
In a separate experiment, it was shown that mannos-
amine inhibited the retinoic acid-induced loss of radio-
Fig. 1. The effect of glucosamine on the loss of aggrecan from
bovine articular cartilage explant cultures cultured in the presence
of retinoic acid. Freshly dissected articular cartilage was incubated
with [35S]sulfate in DMEM containing 20% (v/v) NBCS for 6 h and
returned to culture for 9 days in DMEM (j), DMEM containing
1 µM retinoic acid (M), DMEM containing 1 µM retinoic acid and
2 mM glucosamine (.), 5 mM glucosamine (m) or 10 mM glucos-
amine (♦). A shows cumulative loss of 35S-labeled aggrecan from
the matrix of explant cultures with time. It is expressed as percent-
age of total radiolabeled aggrecan for each time point. B shows
cumulative loss of aggrecan from the matrix of explant cultures
with time. Values represent the mean of duplicate cultures and the
range over the 9 days (error bars).
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labeled and chemical levels of aggrecan in a concentration-
dependent manner [Fig. 2(A, B, respectively)]. In the
presence of 2, 5 and 10 mM mannosamine, the retinoic
acid-stimulated loss of radiolabled aggrecan at the end of
the experiment (day 9) was inhibited by 8, 40 and 100%,
respectively. Table I shows that increasing chemical levels
of aggrecan were retained in the matrix of cultures stimu-
lated with retinoic acid in presence of 2, 5 and 10 mM
mannosamine. Mannosamine appeared to be more potent
than glucosamine.
EFFECTS OF GLUCOSAMINE AND MANNOSAMINE ON
CHONDROCYTE METABOLISM
The effects of glucosamine and mannosamine on lactate
production, protein and proteoglycan syntheses were in-
vestigated in order to determine whether concentrations of
amino sugars observed to inhibit aggrecan loss in explant
cultures of cartilage affected the general metabolism of the
tissue.
The lactate concentrations present in the medium of
explant cultures, presented in Figs. 1 and 2, were deter-
mined on days 5 and 9 (Table II). Higher lactate production
was observed in cultures maintained in the presence of
retinoic acid than in the non-stimulated cultures. This has
been observed by other researchers for cartilage cultures
exposed to retinoic acid14,23,24. For cultures exposed to
retinoic acid and in the presence of 5 and 10 mM of either
of the amino sugars, there was a trend showing a decrease
in lactate production with increasing concentration of amino
sugar (Table II). Bryson et al.14 also reported an increase in
lactate production in IL-1α-treated cultures of bovine nasal
cartilage, and this effect was abrogated in the presence of
5 mM mannosamine. However, Table II shows that lactate
production in the presence of 5 and 10 mM of either of the
amino sugars was 80–95% of levels observed for tissue
cultured in DMEM alone, indicating a significant lactate
production throughout the culture period.
The rate of incorporation of 3H-serine into protein was
measured on days 5 and 9 of culture in articular cartilage
cultures maintained in the presence of 5 or 10 mM glu-
cosamine or mannosamine. There were no significant
differences between different culture conditions for the
incorporation of 3H-serine into protein for cultures main-
tained in the presence of glucosamine or mannosamine
(Table III).
The rates of incorporation of 35S-sulfate into proteo-
glycans were measured on days 5 and 9 of culture in
cartilage explant cultures maintained in presence of glu-
cosamine or mannosamine. The levels of proteoglycan
synthesis in cultures maintained in the absence of retinoic
acid were statistically different between treatment groups.
This was indicated by a 23% decrease in the proteoglycan
synthesis in cultures in the presence of 10 mM glucosa-
mine [Table III(A)] and less than 20% in cultures supple-
mented with 5 and 10 mM mannosamine [Table III(B)].
Similar trends were also observed in duplicate exper-
iments. Table III also shows that exposure of cartilage to
retinoic acid resulted in the suppression of the incorpor-
ation of 35S-sulfate into proteoglycans [Table III(A)]. This is
in agreement with a previous report showing reduction in
proteoglycan synthesis in articular cartilage cultures in the
presence of 1 µM retinoic acid25. It is apparent that the
Table I
Amount of glycosaminoglycans remaining in the matrix of bovine
articular cartilage explant cultures maintained in medium alone,
medium containing retinoic acid or medium containing retinoic acid
and varying concentrations of glucosamine or mannosamine for
9 days
Culture conditions Glycosaminoglycan
concentration
in matrix (µg CS/mg
wet-weight tissue)
Medium alone 10.7±0.2
Medium+retinoic acid 5.8±0.2
Medium+retinoic acid+2 mM glucosamine 6.1±1.6 (6)
Medium+retinoic acid+5 mM glucosamine 6.3±0.5 (10)
Medium+retinoic acid+10 mM glucosamine 8.4±0.8 (53)
Medium+retinoic acid+2 mM mannosamine 6.6±1.5 (16)
Medium+retinoic acid+5 mM mannosamine 8.4±0.1 (53)
Medium+retinoic acid+10 mM
mannosamine
10.0±0.5 (86)
Values are the mean±range of duplicate determinations. Values
in parentheses show the percentage inhibition of the retinoic
acid-stimulated loss of glycosaminoglycans from the matrix. The
stimulated loss of glycosaminoglycans represents the loss above
that observed for cultures maintained in DMEM alone. Articular
cartilage from different animals was used in glucosamine and
mannosamine experiments.
Fig. 2. The effect of mannosamine on the loss of aggrecan from
bovine articular cartilage explant cultures cultured in the presence
of retinoic acid. Freshly dissected articular cartilage was incubated
with [35S]sulfate in DMEM containing 20% (v/v) NBCS for 6 h and
returned to culture for 9 days in DMEM (j), DMEM containing
1 µM retinoic acid (M), DMEM containing 1 µM retinoic acid and
2 mM mannosamine (.), 5 mM mannosamine (m) or 10 mM
mannosamine (♦). A shows cumulative loss of 35S-labeled aggre-
can from the matrix of explant cultures with time. It is expressed as
percentage of total radiolabeled aggrecan for each time point. B
shows cumulative loss of aggrecan from the matrix of explant
cultures with time. Values represent the mean of duplicate cultures
and the range over the 9 days (error bars).
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addition of glucosamine or mannosamine to the culture
medium containing retinoic acid did not affect the proteogly-
can synthesis [Table III(A)]. Overall, the above-mentioned
data indicate that the metabolic activity of the chondrocytes
was not compromised in presence of the amino sugars
over the culture period.
Table II
Lactate production by bovine articular cartilage explants maintained in medium alone, medium containing retinoic acid or medium containing
retinoic acid and varying concentrations of glucosamine or mannosamine for 9 days
Culture conditions Lactate concentration in medium (mg lactate/100 mg wet-weight
tissue/24 h)
Day 5 Day 9
Medium alone 1.01±0.06 1.01±0.00
Medium+retinoic acid 1.40±0.12 1.40±0.04
Medium+retinoic acid+5 mM glucosamine 0.95±0.05 (68) 0.93±0.03 (66)
Medium+retinoic acid+10 mM glucosamine 0.89±0.10 (64) 0.83±0.10 (59)
Medium alone 0.99±0.07 1.03±0.13
Medium+retinoic acid 1.31±0.01 1.30±0.04
Medium+retinoic acid+5 mM mannosamine 0.94±0.02 (72) 0.92±0.07 (71)
Medium+retinoic acid+10 mM mannosamine 0.81±0.08 (61) 0.76±0.08 (58)
Values are the mean±range of duplicate determinations. Values in parentheses are percentage of values observed for cultures maintained
in medium containing retinoic acid.
Table III
Incorporation of [3H]leucine and [35S]sulfate into macromolecules by bovine articular cartilage that was maintained in culture for 5 or 9 days
in presence or absence of retinoic acid and presence or absence of varying concentrations of (A) glucosamine and (B) mannosamine
Culture conditions Days in
culture
[3H]serine incorporation (cpm/100 mg
wet-weight tissue/2 h)
[35S]sulfate incorporation (cpm/100 mg
wet-weight tissue/2 h)
(A) Glucosamine
Medium alone 5 24 075±5745* 54 102±83†
Medium+5 mM glucosamine 5 27 945±2767* (113) 48 084±326† (89)
Medium+10 mM glucosamine 5 25 737±6848* (104) 41 685±136† (77)
Medium alone 9 21 298±2990* 53 322±143†
Medium+5 mM glucosamine 9 19 981±1455* (94) 46 712±877† (88)
Medium+10 mM glucosamine 9 18 232±748* (86) 43 687±518† (82)
Medium+retinoic acid 5 22 009±1454* 37 292±932†
Medium+retinoic acid+10 mM
glucosamine
5 17 154±2504* (78) 42 111±113† (113)
Medium+retinoic acid 9 18 354±3082* 33 520±364†
Medium+retinoic acid+5 mM
glucosamine
9 16 909±835* (92) 36 675±466† (109)
Medium+retinoic acid+10 mM
glucosamine
9 15 131±1645* (82) 35 998±204† (107)
(B) Mannosamine
Medium alone 5 32 221±964* 54 102±83†
Mediun+5 mM mannosamine 5 24 832±1986* (83) 44 639±130† (83)
Medium+10 mM mannosamine 5 26 957±1769* (84) 47 198±66† (87)
Medium alone 9 21 298±299* 53 322±143†
Medium+5 mM mannosamine 9 19 891±1896* (93) 46 777±318† (88)
Medium+10 mM mannosamine 9 22 130±1761* (104) 43 052±591† (81)
Medium+retinoic acid 5 22 009±1454* 37 292±932*
Medium+retinoic acid+5 mM
mannosamine
5 20 682±900* (94) 39 747±357* (107)
Medium+retinoic acid+10 mM
mannosamine
5 18 983±1771* (86) 34 133±911* (92)
Medium+retinoic acid 9 18 354±3082* 33 520±364*
Medium+retinoic acid+5 mM
mannosamine
9 14 882±2465* (81) 35 569±950* (106)
Medium+retinoic acid+10 mM
mannosamine
9 16 712±1660* (91) 35 122±29* (105)
Values are the mean±SD of triplicate determinations. Values in parentheses are percentage of values observed for cultures maintained in
medium alone or medium containing retinoic acid.
*Differences between treatment groups within a set determined by Kruskal–Wallis test were not statistically significant (P>0.05).
†Differences between treatment groups within a set determined by Kruskal–Wallis test were statistically significant (P<0.05).
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EFFECTS OF GLUCOSAMINE AND MANNOSAMINE ON SOLUBLE
AGGRECANASE ACTIVITY
These experiments were undertaken to determine
whether the inhibitory effects of glucosamine and man-
nosamine on the catabolism of aggrecan in articular carti-
lage explant cultures could be attributed to the direct
inhibition of aggrecanase activity. Aggrecan monomer was
digested with aggrecanase activity present in conditioned
medium from explant culture of joint capsule in the pres-
ence of varying concentrations of glucosamine or man-
nosamine21. Figure 3 shows immunoblots of aggrecan core
protein fragments using the monoclonal antibody 5/6/3-B-3.
Three typical bands representing aggrecanase degradation
products of aggrecan with ∼Mr 200 000 (band C), 170 000(band D) and 130 000 (band E) were observed in all
digests. In a number of studies, we have analyzed the
bands of the same electrophoretic mobility by the amino-
terminal amino acid analysis and have shown that these
bands represent aggrecanase-generated aggrecan frag-
ments resulting from cleavages of aggrecan within the
interglobular domain between residues E373–A374 (band
C), and between residues E1480–G1481, E1666–G1667 and
E1771–A1772 (bands C, D and E, respectively) within the
chondroitin sulfate attachment domains13,21,26. Bands of
approximately equal intensity were observed in the ab-
sence (lane b) or presence of 2, 5 and 10 mM glucosamine
(lanes c–e) or mannosamine (lanes f–h), indicating that
glucosamine and mannosamine do not have a direct effect
on aggrecanase activity.
REVERSIBILITY OF SUPPRESSION OF AGGRECAN DEGRADATION
BY GLUCOSAMINE AND MANNOSAMINE
The section, showed effects of Glucosamine and
Mannosamine on Soluble Aggrecanase Activity has shown
that glucosamine and mannosamine do not directly inhibit
aggrecanase activity. These experiments were performed
to investigate if aggrecanase activity remains suppressed
after the withdrawal of glucosamine and mannosamine
from explant cultures of articular cartilage exposed to
retinoic acid. Freshly dissected articular cartilage was incu-
bated with sulfate as described in Materials and Methods
section and maintained in culture for 15 days. Some
cultures were treated with 5 mM glucosamine or man-
nosamine for the first 5 days, as described in Materials and
Methods section.
Figure 4(A) shows that 5 mM glucosamine inhibited the
retinoic acid-stimulated loss of radiolabeled aggrecan by
38% after 5 days in culture. On removal of glucosamine
from culture medium, the enhanced loss of radiolabeled
Fig. 3. The effects of glucosamine and mannosamine on aggreca-
nase activity present in conditioned medium from joint capsule
explants. Aggrecan monomer isolated from bovine articular carti-
lage was incubated with conditioned medium from joint capsule
explant culture in the presence of varying amounts of glucosamine
or mannosamine. The digests were deglycosylated, and the result-
ing aggrecan core protein fragments were resolved on a 4–10%
gradient polyacrylamide gel. Unsaturated chondroitin sulfate dis-
accharides that remained attached to the core protein fragments,
following deglycosylation, were immunodetected using the anti-
body 5/6/3-B-3. Aggrecan core protein of aggrecan monomer
preparation used in digests (lane a), aggrecan core protein frag-
ments isolated from the digestion of aggrecan monomer with
conditioned medium (lane b) or with conditioned medium in the
presence of 2, 5 and 10 mM glucosamine (lanes c–e) or 2, 5 and
10 mM mannosamine (lanes f–h).
Fig. 4. The effect of pretreatment with glucosamine or man-
nosamine on the loss of 35S-labeled aggrecan in adult bovine
articular cartilage cultures exposed to retinoic acid. Freshly dis-
sected articular cartilage was incubated with [35S]sulfate in DMEM
containing 20% (v/v) NBCS for 6 h and returned to culture. (A) The
cultures were maintained for 5 days in DMEM containing 5 mM
glucosamine in the absence (n) or presence ( ) of 1 µM retinoic
acid and continued for another 10 days in DMEM containing 1 µM
retinoic acid. (B) The cultures were maintained for 5 days in DMEM
containing 5 mM mannosamine in the absence (M) or presence
( ) of 1 µM retinoic acid and continued for another 10 days in
DMEM containing 1 µM retinoic acid. The control cultures (A and
B) were maintained for 15 days in DMEM (+) or DMEM containing
1 µM retinoic acid (♦) or 5 days in DMEM and continued for
another 10 days in DMEM containing 1 µM retinoic acid (L). A and
B show cumulative loss of 35S-labeled aggrecan from the matrix of
explant cultures with time. It is expressed as percentage of total
radiolabeled aggrecan for each time point. Values represent
the mean of duplicate cultures and the range over the 15 days
(error bars).
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aggrecan continued, and by day 11 of culture period,
approached the level of loss similar to that for tissue
stimulated with retinoic acid, but not exposed to
glucosamine.
When the tissue was cultured in DMEM in the presence
or absence of 5 mM glucosamine for 5 days, similar rates of
loss of radiolabeled aggrecan were observed for the two
culture conditions [Fig. 4(A)]. On removal of glucosamine
and exposure of these cultures to retinoic acid, similar
enhanced rates of aggrecan loss were observed from day 6
of culture period onwards. By day 11 of culture period, the
levels of loss of radiolabeled aggrecan reached values
similar to those observed for control cultures maintained in
the presence of retinoic acid for entire culture period. At this
point, an inhibition of stimulated aggrecan loss of 26%
would be expected to be achieved in a culture maintained
in presence of 5 mM glucosamine (Fig. 1). Hence, the
stimulation of catabolism of radiolabeled aggrecan was
achieved between 24 and 48 h, following exposure of
cultures to retinoic acid, and was then maintained through-
out the culture period regardless of pretreatment with
glucosamine. Taken together, it appears that exposure of
cartilage to glucosamine either in the presence or absence
of retinoic acid does not provide continuing protection
from aggrecan loss from tissue wherein the catabolism of
aggrecan is stimulated with retinoic acid.
Similar patterns of aggrecan loss were observed in
the experiment with mannosamine. In presence of 5 mM
mannosamine, the stimulated loss of radiolabeled aggre-
can was inhibited in cultures maintained in the presence of
retinoic acid by 54% after 5 days in culture [Fig. 4(B)]. On
removal of mannosamine from culture medium, the en-
hanced loss of radiolabeled aggrecan reached the level of
loss similar to that shown for tissue stimulated with retinoic
acid in the absence of mannosamine by day 11 of culture
period. At this point, an inhibition of stimulated aggrecan
loss of 60% would be expected to be achieved and
maintained in a culture maintained in presence of 5 mM
mannosamine (Fig. 2).
When the tissue was cultured in DMEM in the presence
of 5 mM mannosamine, inhibition of basal loss of radio-
labeled aggrecan was apparent on days 5 and 6 of culture
period [Fig. 4(B)]. Removal of mannosamine and introduc-
tion of retinoic acid resulted in an enhanced rate of aggre-
can loss. Similar results were observed for cultures that
were not treated with mannosamine, but were introduced to
retinoic acid at the same time. By day 11 of culture period,
the levels of loss of radiolabeled aggrecan reached the
values similar to those observed in control cultures main-
tained in the presence of retinoic acid for entire culture
period. Hence, like glucosamine, mannosamine did not
provide a long-term suppression of aggrecan loss from
cultures wherein aggrecan catabolism was stimulated with
retinoic acid.
Discussion
This study shows that glucosamine and mannosamine at
concentrations of up to 10 mM inhibited aggrecanase-
mediated degradation of radiolabeled and chemical aggre-
can in dose-dependent manner in explant cultures of
bovine articular cartilage stimulated with retinoic acid over
a 9-day culture period. Mannosamine was found to have a
greater effect on inhibiting aggrecan degradation than
glucosamine. This is in agreement with previous studies
that used retinoic acid and cytokines IL-1 and TNF-α to
promote catabolism in cartilage and chondrocyte cultures
in presence of these amino sugars4,5,14. These researchers
reported above 80% of inhibition of aggrecan degradation
by retinoic acid-stimulated bovine articular cartilage ex-
plants at lower mannosamine concentrations, at 1 and
1.5 mM5,14, and at 5 mM glucosamine4. The difference with
the present study may be due to the variation in culture
protocols. Calf cartilage was used in one of the studies4,
and in another study, glucose was absent from the culture
medium14.
It was important to determine that the effects of glucosa-
mine and mannosamine on the catabolism of aggrecan
over a 9-day culture period was not due to the impaired
metabolic activity of the chondrocytes. It has been sug-
gested that cellular energy levels may be compromised due
to reduced glucose uptake in presence of glucosamine and
mannosamine, since they are internalized by a common
transport system27–29. Furthermore, ATP levels could be
depleted as the result of enhanced phosphorylation of
glucosamine and mannosamine and reduced regeneration
of ATP from oxidation of the glucose30,31. However, we
observed that concentrations of up to 10 mM glucosamine
or mannosamine did not have an adverse effect on the
metabolism of chondrocytes, as measured by lactate pro-
duction even after 9 days of exposure to the respective
amino sugar. It is surprising that mannosamine at concen-
tration of 10 mM did not have a major effect on the cell
metabolism, since Sandy et al.5 report a significant inhibi-
tion of protein synthesis (40%) in IL-1β-stimulated rat
chondrocyte cultures maintained in presence of 5 mM
mannosamine. In addition, Bryson et al.14 reported a sig-
nificant suppression of protein synthesis in bovine nasal
cartilage maintained in the presence of 1 mM man-
nosamine; however, in IL-1α-stimulated cultures, the pres-
ence of 1 mM mannosamine did not have an effect. It is
possible that the disparity between this work and others
was due to differences between cell and explant cultures
and between articular and nasal cartilage cultures. There-
fore, the inhibition of aggrecan degradation by glucosamine
and mannosamine observed in this study was unlikely to be
the outcome of decreased metabolic activity of articular
cartilage. This agrees with a recent study wherein chondro-
cyte viability was shown not to be compromised by expo-
sure of cartilage to concentrations of glucosamine of up to
11 mM (2.5 mg/ml) for 24 h. However, when incubated with
concentrations of glucosamine of 30 mM (6.5 mg/ml) and
above, significant changes in cell structure and reduced
cell viability were observed32.
This work shows that glucosamine or mannosamine did
not directly inhibit aggrecanase activity, since the presence
of these amino sugars did not inhibit soluble aggrecanase
activity (Fig. 3). In addition, it appeared that mannosamine
was able to inhibit the rate of aggrecan degradation in
cultures maintained in the absence of retinoic acid (Fig. 4).
The loss of aggrecan in non-stimulated cultures is likely
to be due to both the passive loss of aggrecan33 and
aggrecanase activity, since the amino-terminal amino acid
sequence analysis of aggrecan metabolites in cartilage
cultures maintained in DMEM in the absence of retinoic
acid indicates that the proteolytic cleavage of aggrecan
core protein occurs specifically at aggrecanase sites (data
not shown and reference 34). The results in this study
indicate that glucosamine and mannosamine are capable
of modulating the regulation of aggrecanase activity under
condition of catabolic stimulation. In recent studies, ‘aggre-
canase activity’ has been attributed to an increasing
number of aggrecanase proteinases; and so far,
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ADAMTS-1, ADAMTS-4 and ADAMTS-5 have been
detected in cartilage35,36. There is ongoing work investigat-
ing which ADAMTS proteinases are constitutively ex-
pressed and/or induced in cartilage35. It is possible that the
amino sugars are mediators of these processes, or they
may also play a role in the activation of the latent aggreca-
nase proteinases and their distribution within the extra-
cellular matrix37. Furthermore, this ability of amino sugars
to modulate the regulation of aggrecanase activity under
conditions of catabolic stimulation is reversible. This is
shown in Fig. 4, wherein the removal of glucosamine
and mannosamine from retinoic acid-stimulated cultures
results in an immediate loss of suppression of aggrecanase
activity in metabolically active cultures.
The diverse metabolic pathways mediated by amino
sugars have been proposed to have an impact on the
generation of aggrecanase activity. Since mannosamine, in
particular, and also glucosamine have been shown to
inhibit glycosylphosphatidylinositol (GPI) anchor formation,
it has been suggested that the regulation of aggrecanase
activity by these amino sugars is exerted at a posttrans-
lational level, since aggrecanase proteins do not belong to
GPI family of proteins5,7,12,38. A direct involvement of
GPI-anchored proteins in posttranslational processing of
aggrecanase protein(s) is yet to be confirmed5,14. The
impediment of lysosomal function, necessary for the
posttranslational activation of aggrecanases39,40, due to
depletion of ATP levels has also been proposed as a
possible cause of suppression of aggrecanase activity by
amino sugars4,5. The levels of lactate production observed
in this study may provide argument against this suggestion.
A possible role of amino sugars and their biosynthetic
derivatives in signaling pathways and consequent gene
regulation that may affect the expression, secretion and/or
activation of aggrecanases is yet to be explored41. There
is emerging evidence that a biosynthetic derivative of
glucosamine, N-acetylglucosamine, has a prominent role in
the regulation of signaling pathways wherein many intra-
cellular proteins, such as nuclear factors, nuclear pore
proteins, kinases and cytoskeletal macromolecules are
dynamically modified with the addition of O-linked
N-acetylglucosamine42. The amino sugars have been
shown to modulate the expression of several genes in a
number of cell types43,44. Such modulation of proteins
involved in signaling pathways may impact the catabolic
processes. In chondrocytes, glucosamine has been re-
ported to suppress MMP-3 expression in presence of
IL-1β41.
In conclusion, continuous exposure to 5–10 mM glucos-
amine and 2–10 mM mannosamine were required for
suppression of aggrecanase catabolism of aggrecan in
long-term cultures of articular cartilage stimulated with
retinoic acid. At these concentrations of amino sugars, the
metabolism of chondrocytes was not compromised. This
effect was reversible, since the removal of the amino
sugars from the culture medium led to the increased rate of
loss of aggrecan from cartilage. This study suggests that
the long-term protection of cartilage to stimulated aggrecan
loss in osteoarthritis relies on continual presence of glu-
cosamine in plasma, and this is supported by clinical
studies suggesting that the long-term treatment with glu-
cosamine produces beneficial results in the treatment of
osteoarthritis15,45,46. In these studies, glucosamine was
administered orally at a daily dose of 1.5 g. Glucosamine is
rapidly utilized in the biosynthetic processes in body, but
little is known about its bioavailability or pharmacokinetics.
In man, it has been shown that there is a rapid absorption
of glucosamine close to 90% of the oral dose and has a
bioavailability of 26%. Furthermore, the studies in dogs
indicated that glucosamine accumulates in tissues that
includes cartilage47–49. Based on the current literature, the
long-term daily administration of 1.5 g glucosamine in
humans is likely to maintain levels of glucosamine in
cartilage comparable with the lowest concentrations of the
amino sugar used in this study.
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